SNDX - シンダックス・ファ―マシュ―ティカルズ (Syndax Pharmaceuticals Inc.)

SNDXのニュース

   Egle Therapeutics Appoints Pierre Legault as Chairman and Board Member  2022/05/05 09:00:00 Kwhen Finance
   Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) Is 25.64% Above Its 52-Week Low, But How Long Will It Remain So?  2022/04/09 13:00:00 Marketing Sentinel
In last trading session, Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) saw 0.38 million shares changing hands with its beta currently measuring 1.61. Company’s recent per share price level of $17.51 trading at -$1.31 or -6.96% at ring of the bell on the day assigns it a market valuation of $950.27M. That closing price of SNDX’s stock is … Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) Is 25.64% Above Its 52-Week Low, But How Long Will It Remain So? Read More »
   Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs  2022/04/08 04:59:12 Seeking Alpha
   Syndax Pharmaceuticals (SNDX) Presents At Barclays Global Healthcare Conference  2022/03/23 18:21:32 Seeking Alpha
   Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) Is An Exciting Stock To Watch.  2022/03/12 17:00:00 Stocks Register
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares, rose in value on Friday, 03/11/22, with the stock price down by -3.60% to the previous day’s close as strong demand from buyers drove the stock to $16.85. Actively observing the price movement in the last trading, the stock closed the session at $17.48, falling within a range of $16.84 … Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) Is An Exciting Stock To Watch. Read More »
   Incyte and Syndax to jointly develop and commercialise axatilimab  2021/09/28 14:12:17 Pharmaceutical Business Review
Incyte has signed a collaboration and license agreement with Syndax Pharmaceuticals to develop and commercialise axatilimab for chronic graft-versus-host disease (cGVHD) and other fibrotic diseases. Axatilimab is an The post Incyte and Syndax to jointly develop and commercialise axatilimab appeared first on Pharmaceutical Business review .
   Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate  2021/09/27 13:23:11 Benzinga
Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) and Incyte Corporation (NASDAQ: INCY ) have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize Syndax''s axatilimab. Related Content: Syndax Pharma Receives FDA Orphan Drug Designation For Axatilimab For Treatment Of Chronic Graft vs. Host Disease Syndax and Incyte seek to develop axatilimab for chronic graft-versus-host Full story available on Benzinga.com
   Syndax Partners With Incyte To Develop, Commercialize Axatilimab  2021/09/27 10:40:00 FinanzNachrichten
WASHINGTON (dpa-AFX) - Syndax Pharmaceuticals, Inc. (SNDX) and Incyte (INCY) have entered into a worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax''s ant
   Syndax Partners With Incyte To Develop, Commercialize Axatilimab - Quick Facts  2021/09/27 10:19:44 Business Insider Markets
(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX) and Incyte (INCY) have entered into a worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax''s anti-CSF-1R monoclonal antibody. Incyte will lead global commercial activities for axatilimab across all indications. The companies will participate in a 50:
   Syndax Pharmaceuticals Inc (SNDX) President and COO Michael A Metzger Sold $702,741 of Shares  2021/09/23 00:15:01 GuruFocus
Related Stocks: SNDX ,
   Head to Head Review: Syndax Pharmaceuticals (NASDAQ:SNDX) vs. Iterum Therapeutics (NASDAQ:ITRM)  2021/03/13 00:27:10 Modern Readers
Syndax Pharmaceuticals (NASDAQ:SNDX) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings. Volatility & Risk Syndax Pharmaceuticals has a beta of 1.8, suggesting that its share price […]
   Syndax Posts Better-Than-Feared Quarterly Loss, Sales Beat Estimates  2021/03/09 08:38:36 Smarter Analyst
Syndax Pharmaceuticals reported a better-than-expected loss in the fourth quarter and outpaced analysts’ expectations for revenues. Shares of the clinical-stage biopharmaceutical company dropped … The post Syndax Posts Better-Than-Feared Quarterly Loss, Sales Beat Estimates appeared first on Smarter Analyst .
   Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Increased to $29.00 by Analysts at Barclays  2020/11/20 13:08:52 Transcript Daily
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target lifted by Barclays from $23.00 to $29.00 in a report published on Thursday, The Fly reports. Barclays currently has an overweight rating on the stock. Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Syndax Pharmaceuticals from a […]
   The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration  2020/11/17 13:31:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16) Aligos Therapeutics Inc (NASDAQ: ALGS ) (announced multiple presentations at the Liver Meeting) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Champions Oncology Inc (NASDAQ: CSBR ) CureVac BV (NASDAQ: CVAC )(announced a vaccine supply deal with the European Commission) Eidos Therapeutics Inc (NASDAQ: EIDX ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kazia Therapeutics Ltd (NASDAQ: KZIA ) Keros Therapeutics Inc (NASDAQ: KROS ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim efficacy data for the Phase 3 study of its coronavirus vaccine candidate) Myokardia Inc (NASDAQ: MYOK ) Neuronetics Inc (NASDAQ: STIM ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacira Biosciences Inc (NASDAQ: PCRX ) Shockwave Medical Inc (NASDAQ: SWAV ) Spruce Biosciences Inc (NASDAQ: SPRB ) Summit Therapeutics Inc (NASDAQ: SMMT ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) (announced regulatory filing for envafolimab in the indication of MSI-H/dMMR cancer, in China) Trinity Biotech plc (NASDAQ: TRIB ) United Therapeutics Corporation (NASDAQ: UTHR ) Veracyte Inc (NASDAQ: VCYT ) Vericel Corp (NASDAQ: VCEL ) Zai Lab Ltd – ADR (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
   Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 5.7%  2020/10/23 17:48:41 US Banking News
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) rose 5.7% during mid-day trading on Friday . The company traded as high as $16.18 and last traded at $16.01. Approximately 590,192 shares traded hands during mid-day trading, an increase of 20% from the average daily volume of 491,370 shares. The stock had previously closed at $15.14. SNDX has been the […]

calendar